PARP1 and ovarian carcinoma: Nonetheless, despite this strong evidence underpinning the biological rationale of synthetic lethality between HR deficiency deriving from BRCA mutations and PARP inhibitors, a significant PFS improvement was also highlighted in women with BRCA WT ovarian carcinomas randomly assigned to the Olaparib arm versus placebo.